As a triple agonist activating GLP-1, GIP, and glucagon receptors, it provides the most comprehensive receptor coverage available
Human GLP1R variants affecting GLP1R cell surface expression are associated with impaired glucose control and increased adiposity
Calcium: 1,000-1,200mg daily (especially women)
They are rarely tested in large human studies, and small short-term studies do not provide strong evidence 16
16 weeks 3 vials Through 6 mg phase = 52 mg total
Clinical research has demonstrated that GLP-1 medications effectively support metabolic health in women across all reproductive stages, including premenopausal, perimenopausal, and postmenopausal women